Drug discovery in tuberculosis. New drug targets and antimycobacterial agents.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  European journal of medicinal chemistry

• Publication date

  2018-04-25

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ejmech.2018.03.020PMID 29549838
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mycobacterium tuberculosis lysine-ɛ-aminotransferase a potential target in dormancy: Benzothiazole based inhibitors.

  2017cited by this paper
• A Phenotypic Based Target Screening Approach Delivers New Antitubercular CTP Synthetase Inhibitors.

  2017cited by this paper
• Identification and validation of novel drug targets in Mycobacterium tuberculosis.

  2017cited by this paper
• Rational design of drug-like compounds targeting Mycobacterium marinum MelF protein

  2017cited by this paper
• Virtual Screening, pharmacophore development and structure based similarity search to identify inhibitors against IdeR, a transcription factor of Mycobacterium tuberculosis

  2017cited by this paper
• Synthesis and Biological Evaluation of Thiosemicarbazide Derivatives Endowed with High Activity toward Mycobacterium Bovis

  2017cited by this paper
• Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance

  2017cited by this paper
• The Discovery of 2-Aminobenzimidazoles That Sensitize Mycobacterium smegmatis and M. tuberculosis to β-Lactam Antibiotics in a Pattern Distinct from β-Lactamase Inhibitors.

  2017cited by this paper
• Design and Synthesis of 1-((1,5-Bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methylpiperazine (BM212) and N-Adamantan-2-yl-N'-((E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (SQ109) Pyrrole Hybrid Derivatives: Discovery of Potent Antitubercular Agents Effective against Multidrug-Resista

  2016cited by this paper
• Selective small molecule inhibitor of the Mycobacterium tuberculosis fumarate hydratase reveals an allosteric regulatory site

  2016cited by this paper
• Benzothiazinethione is a potent preclinical candidate for the treatment of drug-resistant tuberculosis

  2016cited by this paper
• New direct inhibitors of InhA with antimycobacterial activity based on a tetrahydropyran scaffold.

  2016cited by this paper
• SAR and identification of 2-(quinolin-4-yloxy)acetamides as Mycobacterium tuberculosis cytochrome bc 1 inhibitors

  2016cited by this paper
• Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection.

  2016cited by this paper
• Arrival of Imidazo[2,1-b]thiazole-5-carboxamides: Potent Anti-tuberculosis Agents That Target QcrB.

  2016cited by this paper
• Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis.

  2016cited by this paper
• Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3

  2016cited by this paper
• Open Lab as a source of hits and leads against tuberculosis, malaria and kinetoplastid diseases

  2016cited by this paper
• Design, Syntheses, and Anti-TB Activity of 1,3-Benzothiazinone Azide and Click Chemistry Products Inspired by BTZ043.

  2016cited by this paper
• Synthesis and Antitubercular Activity of New Benzo[b]thiophenes.

  2016cited by this paper
• The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium tuberculosis

  2015cited by this paper
• Development of selective DprE1 inhibitors: Design, synthesis, crystal structure and antitubercular activity of benzothiazolylpyrimidine-5-carboxamides.

  2015cited by this paper
• Pyrrolo[3,4-c]pyridine-1,3(2H)-diones: A Novel Antimycobacterial Class Targeting Mycobacterial Respiration.

  2015cited by this paper
• Lansoprazole is an antituberculous prodrug targeting cytochrome bc1

  2015cited by this paper
• Syntheses and Antituberculosis Activity of 1,3-Benzothiazinone Sulfoxide and Sulfone Derived from BTZ043.

  2015cited by this paper
• DprE1 Is a Vulnerable Tuberculosis Drug Target Due to Its Cell Wall Localization.

  2015cited by this paper
• Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening.

  2015cited by this paper
• Discovery of novel lysine ɛ-aminotransferase inhibitors: An intriguing potential target for latent tuberculosis.

  2015cited by this paper
• Synthesis and antitubercular evaluation of 4-carbonyl piperazine substituted 1,3-benzothiazin-4-one derivatives.

  2015cited by this paper
• Thiophenecarboxamide Derivatives Activated by EthA Kill Mycobacterium tuberculosis by Inhibiting the CTP Synthetase PyrG

  2015cited by this paper
• Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?

  2015cited by this paper
• 2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1.

  2015cited by this paper
• Whole Cell Target Engagement Identifies Novel Inhibitors of Mycobacterium tuberculosis Decaprenylphosphoryl-β-d-ribose Oxidase.

  2015cited by this paper
• Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?

  2015cited by this paper
• Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-β-D-ribose 2'-oxidase.

  2015cited by this paper
• Isolation and Characterization of a Hybrid Respiratory Supercomplex Consisting of Mycobacterium tuberculosis Cytochrome bcc and Mycobacterium smegmatis Cytochrome aa3

  2015cited by this paper
• Whole cell screen based identification of spiropiperidines with potent antitubercular properties.

  2015cited by this paper
• Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls.

  2014cited by this paper
• Novel Insights into the Mechanism of Inhibition of MmpL3, a Target of Multiple Pharmacophores in Mycobacterium tuberculosis

  2014cited by this paper
• Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.

  2014cited by this paper
• Sulfur rich 2-mercaptobenzothiazole and 1,2,3-triazole conjugates as novel antitubercular agents.

  2014cited by this paper
• Towards a new combination therapy for tuberculosis with next generation benzothiazinones

  2014cited by this paper
• Multitarget Drug Discovery for Tuberculosis and Other Infectious Diseases

  2014cited by this paper
• Putting Tuberculosis (TB) To Rest: Transformation of the Sleep Aid, Ambien, and “Anagrams” Generated Potent Antituberculosis Agents

  2014cited by this paper
• Time‐Dependent Diaryl Ether Inhibitors of InhA: Structure–Activity Relationship Studies of Enzyme Inhibition, Antibacterial Activity, and in vivo Efficacy

  2014cited by this paper
• Tuberculosis drug discovery in the post-post-genomic era

  2014cited by this paper
• Lead optimization of 1,4-azaindoles as antimycobacterial agents.

  2014cited by this paper
• Respiratory Flexibility in Response to Inhibition of Cytochrome c Oxidase in Mycobacterium tuberculosis

  2014cited by this paper
• Biological Evaluation of Potent Triclosan‐Derived Inhibitors of the Enoyl–Acyl Carrier Protein Reductase InhA in Drug‐Sensitive and Drug‐Resistant Strains of Mycobacterium tuberculosis

  2014cited by this paper
• Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity.

  2014cited by this paper
• Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of Mycobacterium tuberculosis InhA.

  2014cited by this paper
• Delamanid: A new armor in combating drug-resistant tuberculosis

  2014cited by this paper
• 4-aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity.

  2014cited by this paper
• 1,4-Azaindole, a Potential Drug Candidate for Treatment of Tuberculosis

  2014cited by this paper
• Oxadiazolo pyrrolidine carboxamides as enoyl-ACP reductase inhibitors: design, synthesis and antitubercular activity screening

  2013cited by this paper
• Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis?

  2013cited by this paper
• Improved BM212 MmpL3 Inhibitor Analogue Shows Efficacy in Acute Murine Model of Tuberculosis Infection

  2013cited by this paper
• Thiolates chemically induce redox activation of BTZ043 and related potent nitroaromatic anti-tuberculosis agents.

  2013cited by this paper
• Insights on how the Mycobacterium tuberculosis heme uptake pathway can be used as a drug target.

  2013cited by this paper
• Synthesis and structure-activity relationships evaluation of benzothiazinone derivatives as potential anti-tubercular agents.

  2013cited by this paper
• University of Birmingham Identification of a small molecule with activity against drug-resistant and persistent tuberculosis

  2013cited by this paper
• Preliminary Structure − Activity Relationships and Biological Evaluation of Novel Antitubercular Indolecarboxamide Derivatives Against Drug-Susceptible and Drug-Resistant Mycobacterium tuberculosis Strains

  2013cited by this paper
• Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis.

  2013cited by this paper
• Indolcarboxamide Is a Preclinical Candidate for Treating Multidrug-Resistant Tuberculosis

  2013cited by this paper
• Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis

  2013cited by this paper
• Indoleamides are active against drug-resistant Mycobacterium tuberculosis

  2013cited by this paper
• Fueling Open-Source Drug Discovery: 177 Small-Molecule Leads against Tuberculosis

  2013cited by this paper
• Advancement of Imidazo[1,2-a]pyridines with Improved Pharmacokinetics and nM Activity vs. Mycobacterium tuberculosis

  2013cited by this paper
• Tetrahydropyrazolo[1,5-a]Pyrimidine-3-Carboxamide and N-Benzyl-6′,7′-Dihydrospiro[Piperidine-4,4′-Thieno[3,2-c]Pyran] Analogues with Bactericidal Efficacy against Mycobacterium tuberculosis Targeting MmpL3

  2013cited by this paper
• Biodegradation of nitroaromatic compounds.

  2013cited by this paper
• A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.

  2013cited by this paper
• Advancement of Imidazo[1,2-a]pyridines with Improved Pharmacokinetics and Nanomolar Activity Against Mycobacterium tuberculosis.

  2013cited by this paper
• Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo.

  2013cited by this paper
• Targeting InhA, the FASII enoyl-ACP reductase: SAR studies on novel inhibitor scaffolds.

  2012cited by this paper
• University of Birmingham Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors

  2012cited by this paper
• Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability.

  2012cited by this paper
• Mycobacterium tuberculosis inhibits neutrophil apoptosis, leading to delayed activation of naive CD4 T cells.

  2012cited by this paper
• Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action.

  2012cited by this paper
• SQ109 Targets MmpL3, a Membrane Transporter of Trehalose Monomycolate Involved in Mycolic Acid Donation to the Cell Wall Core of Mycobacterium tuberculosis

  2012cited by this paper
• Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-β-D-ribofuranose 2'-oxidase DprE1.

  2012cited by this paper
• University of Birmingham Identification of Novel Imidazo[1,2-a]pyridine Inhibitors Targeting M. tuberculosis QcrB

  2012cited by this paper
• Identification of Novel Imidazo[1,2-a]pyridine Inhibitors Targeting M. tuberculosis QcrB

  2012cited by this paper
• Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening.

  2012cited by this paper
• Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs.

  2011cited by this paper
• INHIBITION OF MYCOLIC ACID TRANSPORT ACROSS THE MYCOBACTERIUM TUBERCULOSIS PLASMA MEMBRANE

  2011cited by this paper
• The structure-activity relationship of urea derivatives as anti-tuberculosis agents.

  2011cited by this paper
• Switch or Funnel: How RND-Type Transport Systems Control Periplasmic Metal Homeostasis

  2011cited by this paper
• Pyrido[1,2‐a]benzimidazole‐Based Agents Active Against Tuberculosis (TB), Multidrug‐Resistant (MDR) TB and Extensively Drug‐Resistant (XDR) TB

  2011cited by this paper
• REFMAC5 for the refinement of macromolecular crystal structures

  2011cited by this paper
• Overview of the CCP4 suite and current developments

  2011cited by this paper
• Profiling Early Lung Immune Responses in the Mouse Model of Tuberculosis

  2011cited by this paper
• Discovery and characterization of a unique mycobacterial heme acquisition system

  2011cited by this paper
• MmpL3 Is the Cellular Target of the Antitubercular Pyrrole Derivative BM212

  2011cited by this paper
• Identification of a novel pyrrole derivative endowed with antimycobacterial activity and protection index comparable to that of the current antitubercular drugs streptomycin and rifampin.

  2010cited by this paper
• Investigating the structural basis of arylamides to improve potency against M. tuberculosis strain through molecular dynamics simulations.

  2010cited by this paper
• A Slow, Tight Binding Inhibitor of InhA, the Enoyl-Acyl Carrier Protein Reductase from Mycobacterium tuberculosis*

  2010cited by this paper
• Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-β-D-ribose 2'-epimerase DprE1 of Mycobacterium tuberculosis.

  2010cited by this paper
• Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening.

  2009cited by this paper
• The role of the granuloma in expansion and dissemination of early tuberculous infection.

  2009cited by this paper
• Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis

  2009cited by this paper

• Targeting opportunities presented by the pyrimidine biosynthesis pathway in Mycobacterium tuberculosis: a brief review

  2026cites this paper
• Knowledge, attitudes, and practices of healthcare providers in Beijing regarding human immunodeficiency virus and tuberculosis co-infection: A multicenter cross-sectional study.

  2026cites this paper
• Exploring Pyrazole Integrated Thiazole Molecular Hybrids for Antitubercular Activity: Synthesis, Spectral Characterization, DFT, ADME, and Docking Studies

  2025cites this paper
• Clinical trial of DprE1 inhibitors: from bench to bedside

  2025cites this paper
• Recent Advances in Di-, Tri-Substituted Mono-Thiazoles, and Bis-Thiazoles: Factors Affecting Biological Activities, Future Aspects, and Challenges.

  2025cites this paper
• Spirocyclic compounds: potential drug leads in the fight against Mycobacterium tuberculosis.

  2025cites this paper
• Emergence of Non-tuberculous Mycobacteria Infections in Patients with Drug-Resistant Tuberculosis (DR-TB) During Bedaquiline - Containing Treatment

  2025cites this paper
• The Emerging Landscape of Tubercular Targets: A Medicinal Chemistry Approach

  2025influential citation
• Identification of core biomarkers for tuberculosis progression through bioinformatics analysis and in vitro research

  2025cites this paper
• Synthesis, Biological Screening, and Molecular Docking of Hybrid Pyrazole Scaffolds for Antitubercular and Antimicrobial Activity

  2025cites this paper
• Inhibition Potential of Schiff Bases Against the Target Enzymes of Mycobacterium Tuberculosis Using Molecular Docking

  2025cites this paper
• DprE1 Inhibitors in Clinical Trials: A Route Scouting Approach

  2025cites this paper
• Therapeutic potential of spiro compounds against Staphylococcus aureus: a comprehensive review.

  2025cites this paper
• Exploring 1-Azaaurones: A Concise Overview of Synthetic Strategies and Biological Activities.

  2025cites this paper
• Assessment of the Antitubercular Potential of 3-(3-Phenyl-1H-pyrazol-1-yl)-1H-indole Derivatives Using In Vitro and In Silico Approaches

  2025cites this paper
• Biochemical, Biophysical, and Mechanistic Insights on a Putative Oxidoreductase From Mycobacterium tuberculosis That Shares Structural Homology With Tetracycline Destructase

  2025cites this paper
• Natural Products with Potent Antimycobacterial Activity (2000–2024): A Review

  2025cites this paper
• EXPLORATION OF NICOTINOYL HYDRAZINE DERIVATIVES THROUGH IN SILICO STUDIES FOR NOVEL ANTI-TUBERCULAR DRUG DEVELOPMENT

  2025cites this paper
• Recent Developments in Structurally Diverse Anti-Tubercular Drug Molecules and Their Molecular Targets Against Mycobacterium tuberculosis

  2025cites this paper
• Flavonoids: Potential Novel Inhibitors of Mycobacterium tuberculosis

  2025cites this paper
• Discovery of novel fluorene analogues as potent antitubercular agents targeting inhA: Synthesis, optimization, and biological investigation

  2025cites this paper
• Benzimidazole as a Privileged Scaffold in Drug Design and Discovery.

  2024cites this paper
• New coumarin linked thiazole derivatives as antimycobacterial agents: Design, synthesis, enoyl acyl carrier protein reductase (InhA) inhibition and molecular modeling.

  2024cites this paper
• Design, synthesis and computational studies of new azaheterocyclic coumarin derivatives as anti-Mycobacterium tuberculosis agents targeting enoyl acyl carrier protein reductase (InhA)

  2024cites this paper
• Imaging‐based profiling for elucidation of antibacterial mechanisms of action

  2024cites this paper
• Recent advancements in the quest of benzazoles as anti-Mycobacterium tuberculosis agents.

  2024cites this paper
• Structure-based virtual screening approach for identifying DNA gyrase inhibitors of mycobacterium tuberculosis

  2024cites this paper
• Polyketide Synthase 13 (Pks13) Inhibition: A Potential Target for New Class of Anti-tubercular Agents.

  2024cites this paper
• Recent Advances in Pyrimidine-Based Drugs

  2024cites this paper
• Unraveling Dilemmas and Lacunae in the Escalating Drug Resistance of Mycobacterium tuberculosis to Bedaquiline, Delamanid, and Pretomanid.

  2024cites this paper
• In silico design, synthesis and antitubercular activity of novel 2-acylhydrazono-5-arylmethylene-4-thiazolidinones as enoyl-acyl carrier protein reductase inhibitors

  2024cites this paper
• Modulators targeting protein-protein interactions in Mycobacterium tuberculosis.

  2024cites this paper
• Design, synthesis, antiproliferative, antituberculosis and in-silico analysis of New Schiff base derivatives of cyclohepta[b]thiophene

  2024cites this paper
• Isatin-pyrimidine hybrid derivatives as enoyl acyl carrier protein reductase (InhA) inhibitors against Mycobacterium tuberculosis.

  2023cites this paper
• Convenient and green synthesis of novel 1,2,5-trisubstituted benzimidazole compounds and their antibacterial activity evaluation

  2023cites this paper
• A Review of the Development of Multitarget Molecules against HIV-TB Coinfection Pathogens

  2023cites this paper
• Structure-activity relationship mediated molecular insights of DprE1 inhibitors: A Comprehensive Review

  2023cites this paper
• Target Identification in Anti-Tuberculosis Drug Discovery

  2023cites this paper
• Study of the Rv1417 and Rv2617c Membrane Proteins and Their Interactions with Nicotine Derivatives as Potential Inhibitors of Erp Virulence-Associated Factor in Mycobacterium tuberculosis: An In Silico Approach

  2023cites this paper
• Structural Optimization of Antimycobacterial Azaaurones Towards Improved Solubility and Metabolic Stability

  2023cites this paper
• Revolutionizing Tuberculosis Treatment: Uncovering New Drugs and Breakthrough Inhibitors to Combat Drug-Resistant Mycobacterium tuberculosis.

  2023cites this paper
• Identification of potential molecular targets and repurposed drugs for tuberculosis using network-based screening approach, molecular docking, and simulation

  2023cites this paper
• Discovery of 1,2,3-triazole incorporated indole-piperazines as potent antitubercular agents: Design, synthesis, in vitro biological evaluation, molecular docking and ADME studies.

  2023cites this paper
• Focused Insights Into Emerging Pyrimidine Molecules with Multifarious Anti-Infective Perspectives

  2023cites this paper
• Synthesis, characterization, anti-tuberculosis activity and molecular modeling studies of thiourea derivatives bearing aminoguanidine moiety

  2022cites this paper
• The pathogenic mechanism of Mycobacterium tuberculosis: implication for new drug development

  2022cites this paper
• Advances in the design of combination therapies for the treatment of tuberculosis

  2022cites this paper
• Recent Advances of DprE1 Inhibitors against Mycobacterium tuberculosis: Computational Analysis of Physicochemical and ADMET Properties

  2022cites this paper
• MmpL3 Inhibition as a Promising Approach to Develop Novel Therapies against Tuberculosis: A Spotlight on SQ109, Clinical Studies, and Patents Literature

  2022cites this paper
• An insight into the discovery, clinical studies, compositions, and patents of macozinone: A drug targeting the DprE1 enzyme of Mycobacterium tuberculosis.

  2022cites this paper
• Advances in Key Drug Target Identification and New Drug Development for Tuberculosis

  2022cites this paper
• An Overview on Applications of SwissADME Web Tool in the Design and Development of Anticancer, Antitubercular and Antimicrobial agents: A Medicinal Chemist's Perspective

  2022cites this paper
• Mycobacterium tuberculosis and Pulmonary Rehabilitation: From Novel Pharmacotherapeutic Approaches to Management of Post-Tuberculosis Sequelae

  2022cites this paper
• Tuberculosis Drug Discovery: Challenges and New Horizons.

  2022cites this paper
• K-mer applied in Mycobacterium tuberculosis genome cluster analysis.

  2022cites this paper
• Urea derivatives carrying a thiophenylthiazole moiety: Design, synthesis, and evaluation of antitubercular and InhA inhibitory activities

  2022influential citation
• A holistic molecular modelling approach to design novel indole-2-carboxamide derivatives as potential inhibitors of MmpL3

  2022cites this paper
• Recent Applications of the Multicomponent Synthesis for Bioactive Pyrazole Derivatives

  2022cites this paper
• Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance.

  2021cites this paper
• Early Drug Development and Evaluation of Putative Antitubercular Compounds in the -Omics Era

  2021cites this paper
• Antibacterial activity of a new monocarbonyl analog of curcumin MAC 4 is associated with divisome disruption.

  2021cites this paper
• Deletion of Rv2571c Confers Resistance to Arylamide Compounds in Mycobacterium tuberculosis

  2021cites this paper
• Design, synthesis and biological evaluation of novel 1,2,3-triazole analogues of Imidazo-[1,2-a]-pyridine-3-carboxamide against Mycobacterium tuberculosis.

  2021cites this paper
• Synthetic molecules as DprE1 inhibitors: A patent review

  2021cites this paper
• Targeting Mycobacterium tuberculosis CoaBC through Chemical Inhibition of 4′-Phosphopantothenoyl-l-cysteine Synthetase (CoaB) Activity

  2021cites this paper
• Biosynthetic versatility of marine-derived fungi on the delivery of novel antibacterial agents against priority pathogens.

  2021cites this paper
• Synthesis and structure-activity relationship of new chalcone linked 5-phenyl-3-isoxazolecarboxylic acid methyl esters potentially active against drug resistant Mycobacterium tuberculosis.

  2021cites this paper
• Deletion of Rv2571c Confers Resistance to Arylamide Compounds in <named-content content-type='genus-species'>Mycobacterium tuberculosis</named-content>

  2021cites this paper
• Global scenario and recent advances in molecular diagnosis and management of drug-resistant tuberculosis

  2021cites this paper
• Біологічно орієнтований синтез ліків ( BIODS ) на основі гетерилпохідних 2 , 5-дизаміщених 1 , 3 , 4-оксадіазолів ( Частина 2 )

  2020cites this paper
• An overview of new antitubercular drugs, drug candidates, and their targets

  2020cites this paper
• Solid-phase synthetic approach towards new pyrimidines as potential antibacterial agents

  2020cites this paper
• Different ways to transport ammonia in human and Mycobacterium tuberculosis NAD+ synthetases

  2020cites this paper
• Bis-(imidazole/benzimidazole)-pyridine derivatives: synthesis, structure and antimycobacterial activity

  2020cites this paper
• Discovery of hydrazone containing thiadiazoles as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.

  2020cites this paper
• Construction and Use of Transposon MycoTetOP2 for Isolation of Conditional Mycobacteria Mutants

  2020cites this paper
• Recent strategic developments in the use of superdisintegrants for drug delivery.

  2020cites this paper
• 4-Substituted picolinohydrazonamides as a new class of potential antitubercular agents.

  2020cites this paper
• Promiscuous Targets for Antitubercular Drug Discovery: The Paradigm of DprE1 and MmpL3

  2020cites this paper
• Molecule Property Analyses of Active Compounds for Mycobacterium Tuberculosis.

  2020cites this paper
• Mycobacterial Cell Wall: A Source of Successful Targets for Old and New Drugs

  2020cites this paper
• The literature of heterocyclic chemistry, part XVIII, 2018

  2020cites this paper
• Indole chalcones: Design, synthesis, in vitro and in silico evaluation against Mycobacterium tuberculosis.

  2020cites this paper
• Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus

  2020cites this paper
• Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.

  2020cites this paper
• Structure-based drug design, synthesis and screening of MmaA1 inhibitors as novel anti-TB agents

  2020cites this paper
• Emergence of nontuberculous mycobacteria infections during bedaquiline-containing regimens in multidrug-resistant tuberculosis patients.

  2020cites this paper
• Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.

  2020cites this paper
• Lead molecules from natural products: Insight into tubercular targets

  2020cites this paper
• Opportunities and challenges for flavonoids as potential leads for the treatment of tuberculosis

  2020cites this paper
• Addressing Latent Tuberculosis: New Advances in Mimicking the Disease, Discovering Key Targets, and Designing Hit Compounds

  2020influential citation
• Design, synthesis and antimycobacterial evaluation of novel adamantane and adamantanol analogues effective against drug-resistant tuberculosis.

  2020cites this paper
• Chemical Tools for Illumination of Tuberculosis Biology, Virulence Mechanisms, and Diagnosis.

  2020cites this paper
• Insights into comparative molecular docking study of selected novel thiophene derivative vs standard anti-tubercular drugs against Mycobacterium tuberculosis target enzymes

  2020cites this paper
• Identification of potential non-nucleoside MraY inhibitors for tuberculosis chemotherapy using structure-based virtual screening

  2020cites this paper
• Crystal structure of M. tuberculosis glutamine-dependent NAD+ synthetase complexed with Sulfonamide derivative 1, pyrophosphate, and glutamine

  2020cites this paper
• Design, synthesis and antimycobacterial activity of less lipophilic Q203 derivatives containing alkaline fused ring moieties.

  2019cites this paper
• Synthesis and antitubercular activity of triazole-linked 1,4-benzoquinone derivatives

  2019cites this paper
• Novel benzimidazole-acrylonitrile hybrids and their derivatives: Design, synthesis and antimycobacterial activity.

  2019cites this paper
• Molecular modeling of a series of dehydroquinate dehydratase type II inhibitors of Mycobacterium tuberculosis and design of new binders

  2019cites this paper